DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Healthcare
Updated 1m ago
OMDA logo

Omda ASOB:OMDA Stock Report

Market Cap NOK 904.4m
Updated 1m ago
Share Price
n/a
1Y-10.4%
7D1.7%
1D-2.5%
Portfolio Value
​
View

Omda AS

OB:OMDA Stock Report

Market Cap: NOK 904.4m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Omda (OMDA) Stock Overview

Provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally. More details

OMDA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Trading at 46.9% below our estimate of its fair value

Earnings are forecast to grow 101.88% per year

Trading at good value compared to peers and industry

Risk Analysis

OMDA has negative shareholders equity.

Does not have a meaningful market cap (NOK904M)


OMDA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
14.0% undervalued intrinsic discount
AnalystConsensusTarget
•3mo ago

Healthcare Digitization Will Spark Competitive Gains Amid Regulatory Pressures

124
1
1

Top Analyst Narratives

OMDA logo
Omda
14.0% undervalued intrinsic discount

Healthcare Digitization Will Spark Competitive Gains Amid Regulatory Pressures

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 2 Jun
Read Narrative
View all narratives

Omda AS Competitors

Nordhealth

Symbol: OB:NORDH
Market cap: NOK 2.0b

ContextVision

Symbol: OB:CONTX
Market cap: NOK 307.0m

CodeLab Capital

Symbol: OB:CODE
Market cap: NOK 68.5m

Gentian Diagnostics

Symbol: OB:GENT
Market cap: NOK 618.3m

Price History & Performance

Summary of share price highs, lows and changes for Omda
Historical stock prices
Current Share PriceNOK 43.00
52 Week HighNOK 51.80
52 Week LowNOK 33.00
Beta0.42
1 Month Change16.22%
3 Month Change18.46%
1 Year Change-10.42%
3 Year Change26.10%
5 Year Change-50.57%
Change since IPO-48.19%

Recent News & Updates

User avatar
Narrative Update • Jun 02

OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential

Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.
Analysis Article • May 23

Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target

Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...

Recent updates

User avatar
Narrative Update • Jun 02

OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential

Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.
Analysis Article • May 23

Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target

Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...
User avatar
Narrative Update • May 10

OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential

Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.
User avatar
Narrative Update • Apr 20

OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential

Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.
User avatar
Narrative Update • Apr 06

OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside

The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.
User avatar
Narrative Update • Mar 23

OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside

Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.
User avatar
Narrative Update • Mar 08

OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside

Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.
User avatar
Narrative Update • Feb 22

OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside

Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.
User avatar
Narrative Update • Feb 07

OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside

Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.
User avatar
Narrative Update • Jan 24

OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside

Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.
User avatar
Narrative Update • Jan 10

OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential

Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.
User avatar
Narrative Update • Dec 22

OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside

Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.
User avatar
Narrative Update • Dec 08

OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside

Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.
User avatar
Narrative Update • Nov 24

OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum

Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.
Analysis Article • Oct 10

Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
User avatar
Narrative Update • Aug 23

M&A And Competition Will Shape Risk And Opportunity In Healthcare

Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.
Analysis Article • May 23

Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...
Analysis Article • May 16

These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
User avatar
New Narrative • May 08

Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency

Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.
Analysis Article • Apr 08

Little Excitement Around Omda AS' (OB:OMDA) Revenues

Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...
Analysis Article • Jan 26

Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Dec 21

The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet

Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...
Analysis Article • Nov 13

Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Analysis Article • Jul 24

Returns At Omda (OB:OMDA) Are On The Way Up

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...
Analysis Article • May 22

Omda's (OB:OMDA) Earnings Are Weaker Than They Seem

Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...
Analysis Article • Mar 24

Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified

Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...
Analysis Article • Jan 24

Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)

When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...
Analysis Article • Nov 18

Omda's (OB:OMDA) Earnings May Just Be The Starting Point

Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...
Analysis Article • Jun 17

Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?

Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...

Shareholder Returns

OMDANO Healthcare ServicesNO Market
7D1.7%-0.9%0.8%
1Y-10.4%-14.1%23.2%

Return vs Industry: OMDA exceeded the Norwegian Healthcare Services industry which returned -14.1% over the past year.

Return vs Market: OMDA underperformed the Norwegian Market which returned 23.2% over the past year.

Price Volatility

Is OMDA's price volatile compared to industry and market?
OMDA volatility
OMDA Average Weekly Movement4.7%
Healthcare Services Industry Average Movement5.5%
Market Average Movement4.7%
10% most volatile stocks in NO Market10.4%
10% least volatile stocks in NO Market2.6%

Stable Share Price: OMDA has not had significant price volatility in the past 3 months compared to the Norwegian market.

Volatility Over Time: OMDA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999249Sverre Flatbyomda.com

Omda AS provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally. The company offers laboratory information management systems consisting of Omda ProSang, a blood, cell, and tissue management system; and medical medication solution comprising Omda Cytodose, an oncology medication management solution. It also provides connected healthcare solutions, including Omda Cardio, an ECG and diagnostic storage tool; Omda CIMA, a clinical imaging mobile application; Omda Media, a web-based medical imaging solution; Omda Medimaker, an image management and workflow solution; Omda Picsara, an image management solution; Omda Arcidis, an integrated teleradiology system; Omda Helsemail, a patient data transfer tool; Omda Plutus, an audit and workflow monitoring platform; Omda S7, an e-care communications platform; and Omda XDS, a patient data storage and management solution.

Omda AS Fundamentals Summary

How do Omda's earnings and revenue compare to its market cap?
OMDA fundamental statistics
Market capNOK 904.39m
Earnings (TTM)-NOK 31.11m
Revenue (TTM)NOK 499.07m
1.8x
P/S Ratio
-28.3x
P/E Ratio

Is OMDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OMDA income statement (TTM)
RevenueNOK 499.07m
Cost of RevenueNOK 256.18m
Gross ProfitNOK 242.88m
Other ExpensesNOK 274.00m
Earnings-NOK 31.11m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 18, 2026

Earnings per share (EPS)-1.52
Gross Margin48.67%
Net Profit Margin-6.23%
Debt/Equity Ratio-2,438.6%

How did OMDA perform over the long term?

See historical performance and comparison

Dividends

1.1%
Current Dividend Yield
-31%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 17:02
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Omda AS is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristian StøleCarnegie Investment Bank AB
Emilie EngenDNB Carnegie
Eirik RafdalDNB Carnegie

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide